Grifols Class A/€GRF
1D1W1MYTD1Y5YMAX
Capital at risk
About Grifols Class A
Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.
- Ticker
- €GRF
- Sector
- Health
- Primary listing
- BME
- Employees
- 25,258
- Headquarters
- Barcelona, Spain
- Website
- www.grifols.com
Grifols Class A Metrics
BasicAdvanced
€5.9B
14.88
€0.66
1.19
€0.07
0.68%
Price and volume
Market cap
€5.9B
Beta
1.19
52-week high
€12.90
52-week low
€8.46
Average daily volume
1.3M
Dividend rate
€0.07
Financial strength
Current ratio
2.373
Quick ratio
0.686
Long term debt to equity
110.376
Total debt to equity
117.243
Dividend payout ratio (TTM)
28.32%
Interest coverage (TTM)
2.24%
Profitability
EBITDA (TTM)
1,645.231
Gross margin (TTM)
37.79%
Net profit margin (TTM)
6.09%
Operating margin (TTM)
18.18%
Effective tax rate (TTM)
19.16%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
4.10%
Return on equity (TTM)
6.93%
Valuation
Price to earnings (TTM)
14.879
Price to revenue (TTM)
0.905
Price to book
1.06
Price to tangible book (TTM)
-1.14
Price to free cash flow (TTM)
10.479
Free cash flow yield (TTM)
9.54%
Free cash flow per share (TTM)
0.937
Dividend yield (TTM)
0.68%
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
46.08%
3-year revenue growth (CAGR)
4.63%
10-year revenue growth (CAGR)
6.41%
3-year earnings per share growth (CAGR)
329.35%
10-year earnings per share growth (CAGR)
-1.77%
What the Analysts think about Grifols Class A
Analyst ratings (Buy, Hold, Sell) for Grifols Class A stock.
Analyst projections of the future price of Grifols Class A stock.
Bulls say / Bears say
Robust full-year 2025 performance with revenue up 7.0% cc to €7,524 million and net profit more than doubling to €402 million, driven by strong Biopharma growth, while free cash flow pre-M&A rose to €468 million and leverage decreased to 4.2x with €1.7 billion liquidity (Reuters)
Guidance for 2026 core earnings growth of over 25%, underscoring a strategic pivot to profitability and continued debt reduction after 2025’s strong cash flow generation (Reuters)
Strategic optimization of the global plasma footprint—ramping Egyptian volumes and reallocating U.S. plasma to ex-U.S. markets—enhances supply resilience and cost efficiency under its self-sufficiency platforms (Reuters)
Leverage remains elevated with a net leverage ratio of 4.3x at the end of Q1 2026, constraining financial flexibility for growth initiatives (SEC)
First-half 2026 revenue growth decelerated to just 2.6% cc vs. 7.0% cc in 2025, signaling slowing top-line momentum in its core Biopharma business (SEC)
Q1 2026 EBITDA faced €23 million of FX headwinds from a softer U.S. dollar, partially offsetting operational efficiency gains and pressuring margins (SEC)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Grifols Class A Financial Performance
Revenues and expenses
Grifols Class A Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Grifols Class A
AllEURGBPUSD
Fund name | Fund size | €GRF weighting |
|---|---|---|
Xtrackers Spain€XESD | €269M | 0.33% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.18% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.18% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.18% |
iShares Dow Jones Eurozone Sustainability Screened€EXXV | €217M | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.